State of the art of nanobiotechnology applications in neglected diseases

Current Nanoscience

Volumn 5, Issue 4, 2009, Pages 396-408

  Durán, Nelson ^a   Marcato, Priscyla D ^a   Teixeira, Zaine ^a   Durán, Marcela ^a   Costa, Fabio T M ^a   Brocchi, Marcelo ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Filarial infection; Leishmaniasis; Leprosy; Malaria; Nanobiotechnology; Neglected diseases; Schistosomiasis; Trypanosomiasis; Tuberculosis

Indexed keywords

FILARIAL INFECTION; LEISHMANIASIS; LEPROSY; MALARIA; NEGLECTED DISEASES; SCHISTOSOMIASIS; TRYPANOSOMIASIS; TUBERCULOSIS;

DRUG DELIVERY; ENZYME INHIBITION; LIPOSOMES; PHOSPHOLIPIDS;

NANOBIOTECHNOLOGY;

AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; ANTIMONY GLUCONATE; ARTESUNATE; BENZNIDAZOLE; CHITOSAN; CHLOROQUINE; CIPROFLOXACIN; CLOFAZIMINE; DIETHYLCARBAMAZINE; ETANIDAZOLE; GELATIN; HALOFANTRINE; IVERMECTIN; LIPOSOME; MACROGOL; MALARIA VACCINE; MEGLUMINE ANTIMONATE; NANOPARTICLE; NIFURTIMOX; POLYGLACTIN; PRAZIQUANTEL; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; STIBOGLUCONATE SODIUM; TETRACYCLINE; TUFTSIN; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; BRAIN MALARIA; CHAGAS DISEASE; DRUG ACCUMULATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; FILARIASIS; HUMAN; LEISHMANIASIS; LEPROSY; LIPOSOMAL DELIVERY; MALARIA; MALARIA FALCIPARUM; NANOBIOTECHNOLOGY; NANOENCAPSULATION; NONHUMAN; ONCHOCERCIASIS; PRIORITY JOURNAL; REVIEW; SCHISTOSOMIASIS; SINGLE DRUG DOSE; TRYPANOSOMIASIS; TUBERCULOSIS; VACCINATION;

EID: 70350761694     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341309789378069     Document Type: Review

References (143)

1. Kayser, O.; Lemke, A.; Hernandez-Trejo, N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr. Pharm. Biotechnol., 2005, 6, 3-5. (Pubitemid 40246748)
2. Nahar, M.; Dutta, T.; Murugesan, S.; Asthana, A.; Mishra, D.; Raikumar, V.; Tare, M.; Saraf, S.; Jain, N.K. Functional polymeric nanoparticles; An efficient and promising tool for active delivery of bioactives. Crit. Rev. Ther. Drug Carrier Syst., 2006, 23, 259-318.
3. Couvreur, P.; Vauthier, C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res., 2006, 23, 1417-1450.
4. Gill, S.; Löbenberg, R.; Ku, T.; Azarmi, S.; Roa, W.; Prenner, E.J. Nanoparticles: Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - A Review. J. Biomed. Nanotechnol., 2007, 3, 107-119. (Pubitemid 351877160)
5. Barratt, G.; Bretagne, S. Optimizing efficacy of Amphotericin B through nanomodification. Int. J. Nanomed., 2007, 2, 301-313. (Pubitemid 350047775)
6. Sung, J.C.; Pulliam, B.L.; Edwards, D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol., 2007, 25, 563-570.
7. Mohamed, F.; van der Walle, C.F. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J. Pharm. Sci., 2008, 97, 71-87.
8. Alving, C.R. Liposomes as drug carriers in leishmaniasis and malaria. Parasitol. Today, 1986, 2, 101-107. (Pubitemid 17035889)
9. Kayser. O.; Kiderlen, A.F. Delivery strategies for antiparasitics. Exp. Opin. Investig. Drugs, 2003, 12, 197-207.
10. Durán, N. Brazilian Nanobiotechnology Network MCT/CNPq-Brazil. 2004 (www.mct.gov.br/upd-blob/0007/7565.pdf). [Accessed: March 1, 2007].
11. Ehrenberg, J.P.; Ault, S.K. Neglected diseases of neglected populations: thinking to reshape the determinants of health in Latin Americas and Caribbean. BMC Public Health, 2005, 5, 119. (doi:10.1186/1471-2458-5-119).
12. Renslo, A.R.; McKerrow, J.H. Drug discovery and development for neglected parasitic diseases. Nat. Chem. Biol., 2006, 2, 701-710. (Pubitemid 44764212)
13. Date. A.A. ; Joshi, M.D. ; Patravale, V.B. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev., 2007, 59, 5005-5521
14. Talisuna, A.O.; Bloland, P.; D'Alessandro, U. History, dynamics, and public health importance of malaria parasite resistance. Clin. Microbiol. Rev., 2004, 17, 235-254.
15. White, N.J. Antimalarial drug resistance. J. Clin. Invest., 2004, 113, 1084-1092.
16. Meshnick, S.R. Artemisinin: mechanism of action, resistance and toxicity. Int. J. Parasitol., 2002, 32, 1655-1660
17. Golenser, J.; Waknine, J.H.; Krugliak, M.; Hunt, N.H.; Grau, G.E. Current perspectives on the mechanism of action of artemisinins. Int. J. Parasitol., 2006, 36, 1427-1441.
18. WHO-2000 (http://www.who.int/inf-pr-2000/en/pr2000-02.html)
19. WHO-2005 (www.who.int/intellectualproperty/events/OpenForumCarlosMorel. pdf)
20. Soppimath, K.S.; Aminabhavi, T.M.; Kulkarni, A.R.; Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release, 2001, 20, 1-20. (Pubitemid 32144788)
21. Panyan. J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 2003, 55, 329-347. (Pubitemid 36297053)
22. Papagiannaros, A.; Bories, C.; Demetzos, C.; Loiseau, P. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomed. Pharmacother., 2005, 59, 545-550.
23. Owais, M.; Varshney, G.C.; Choudhury, A.; Chandra, S.; Gupta, C.M. Chloroquine encapsulation in malaria-infected erythtocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in mice. Antimicrob. Agents Chemother., 1995, 39, 180-184.
24. Sessa, G.; Weissman, G. Phosholipid spherules (liposomes) as a model for biological membranes. J. Lipid Res., 1968, 9, 310-315.
25. Couvreur, P.; Kante, B.; Roland, M.; Guioto, P.; Bauduin, P.; Speiser, P. Polyyanoacrylate nanocapsules as potential lysosomotropic carriers - Preparation, morphological and sorptive properties. J. Pharm. Pharmacol., 1979, 31, 331-332.
26. Muller, R.H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50, 161-177. (Pubitemid 30326695)
27. Muller, R.H.; Radtke, M.; Wissing, S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev., 2002, 54, S131-S155.
28. Farmabrasilis (www.farmabrasilis,org.br). Accessed: June 22, 2008.
29. Gabriels, M.; Plaizier-Vercammen, J.A. Physical and chemical evaluation of liposomes, containing Artesunate. J. Pharm. Biomed. Anal., 2003, 31, 655-667.
30. Chimanuka, B.; Gabriels, M.; Detaevernier, M.R.; Plaizier-Vercammen, J.A. Preparation of beta-arthemer liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitemia in Plasmodium chabaudi ma laria-infected mice. J. Pharm. Biomed. Anal., 2002, 28, 13-22.
31. Postma, N.S.; Crommelin, D.J.A.; Eling, W.M.C.; Zuidema, J. Treatment with liposome-bound recombinant tumor necrosis factor-a suppresses parasitemia and protects against Plasmodium berghei K173-induced experimental cerebral malaria in mice. J. Pharmacol. Exp. Ther., 1999, 288, 114-120. (Pubitemid 29113481)
32. Longmuir, K.J.; Robertson, R.T.; Haynes, S.M.; Baratta, J.L.; Waring, A.J. Effective targeting of liposomes to liver and hepatocytes in vivo by incorporation of plasmodium amino acid sequence. Pharm. Rev., 2006, 23, 759-769.
33. Richards, R.L.; Rao, M.; Wassef, N.M.; Glenn, G.M.; Rothwell, S.W.; Alving CR. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect. Immun., 1998, 66, 2859-2865.
34. Alonso, P.L.; Sacarlal, J.; Aponte, J.J.; Leach, A.; Macete, E.; Milman, J.; Mandomando, I.; Spiessens, B.; Guinovart, C.; Espasa, M.; Bassat, Q.; Aide, P.; Ofori-Anyinam, O.; Navia, M.M.; Corachan, S.; Ceuppens, M.; Dubois, M.C.; Demoitié, M.A.; Dubovsky, F.; Menéndez, C.; Tornieporth, N.; Ballou, W.R.; Thompson, R.; Cohen, J. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet, 2005, 366, 2012-2018.
35. Piñero, J.; Temporal, R.M.; Silva-Gonçalves, A.J.; Jimenez, I.A.; Bazzocchi, I.L.; Oliva, A.; Perera, A.; Leon, L.L.; Villadares, B. New administration modelo trans-chalcone biodegradable polymer for the treatment of experimental leishmaniasis. Acta Trop., 2006, 98, 59-65.
36. Alving, C.; Wails, V.; Hanson, W. Liposomes in leishmaniasis: effects of parasite virulence on treatment of experimental leishmaniasis in hamsters. Ann. Trop. Med. Parasitol., 1984, 78, 279-2896.
37. New, R.; Chance, M. Treatment of experimental cutaneous leishmaniasis by liposome-en-trapped pentostan. Acta Trop., 1980, 37, 253-256. (Pubitemid 11192493)
38. Amato, V.; Rabello, A.; Rotondo-Silva, A.; Kono, A.; Maldonado, P.T.H.; Alves, I.; Floeter-Winter, L.; Neto, V.; Shikanai-Yasuda, M. Successful treatment of cutaneous leishmaniasis with lipid formulation of amphotrericn B in two immunocompromised patients. Acta Trop., 2004, 92, 127-132. (Pubitemid 39180014)
39. Berman, J.; Alving, C.; Hanson, W.; Chapman, W.; Lopez-Berestein, G. Antisleishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Amtimicrob. Agents Chemother., 1986, 30, 847-851.
40. Yardley, V.; Croft, S. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents, 2000, 13, 243-248. (Pubitemid 30072740)
41. Adler-Moore, J.P.; Proffitt, R.T. Development, characterization, efficacy and mode of action of Ambisome®, a unilamellar liposome formulation of amphotericin B. J. Liposome Res., 1993, 3, 429-450.
42. Sarkar, S.; Mandal, S.; Sinhá, J.; Mukhopadhyay, S.; Das, N.; Basu, M. Quercetin: critical evaluation as na antileishmanial agent in vivo in hamsters using different vesicular delivery modes. J. Drug Target., 2002, 10, 573-578. (Pubitemid 36124356)
43. Das, N.; Mahato, S.; Naskar, K.; Ghosh, D.; Basu, M. Targeting of urea stimamine encapsulated in liposomos to reticuloendothelial system for the treatment of experimental leishmaniasis. Biochem. Med. Metab. Biol., 1990, 43, 133-139. (Pubitemid 20175786)
44. Banerjee, G.; Bhaduri, A.; Basu, M. Mannose coated liposomal hamycin in the treatment of experimental leishmaniasis in hamster. Biochem. Med. Metab. Biol., 1994, 53, 1-7. (Pubitemid 24339013)
45. Banerjee, G.; Nandi, G.; Mahato, S.; Pakrashi, A.; Basu, M. Drug delivery system: targeting of pentamidines to specific sites using sugar-grafted liposomes. J. Anticrob. Chemother., 1996, 38, 145-150. (Pubitemid 126449219)
46. Sinha, J.; Mukhopadhyay, S.; Das, N.; Basu, M. Targeting of liposomal andrographolide to L donovani-infected macrophages in vivo. Drug Deliv., 2000, 7, 209-213. (Pubitemid 32057552)
47. Chakraborty, R.; Dasgupta, D.; Adhya, S.; Basu, M. Cationic liposome-encapsulated antisense oligonucleotide mediate efficient killing of intracellular Leishmania. Biochem. J., 1999, 340, 393-396. (Pubitemid 29286557)
48. Dasgupta, D.; Adhya, S.; Basu, M. The effect of beta tubulin pecific antine oligonucelotide, encapsulated in different cationic liposomes on the supression of intrecellular L. donovani parasites in vitro. J. Biochem., 2002, 132, 23-27. (Pubitemid 34832266)
49. Agrawal, A.; Gupta C. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv. Drug Deliv. Rev., 2000, 41, 135-146. (Pubitemid 30122954)
50. Guro, P., Agrawal, A.; Singha, U.; Singhal, A.; Gupta, C. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes a drug vehicles. FEBS Lett., 1989, 245, 204-208. (Pubitemid 19076232)
51. Banerjee, G.; Medda, M.; Basu M. A novel peptide-grafted liposomal delivery system targeted to macrophages. Antimocrob. Agents Chemother., 1998, 42, 348-351. (Pubitemid 28114443)
52. Kole, L.; Das, L.; Das P. Synergistic effect of interferon gamma and mannoylated liposome incorporated doxorubicin in the therapy of experimental visceral leihmaniasis. J. Infect. Dis., 1999, 180, 811-820. (Pubitemid 29411368)
53. Frezard, F.; Schettini, D.A.; Rocha, O.G.F.; Demicheli, C. Liposomes: physicochemical and pharmacological properties, applications in antimony-based chemotherapy. Quim. Nova, 2005, 28, 511-518. (Pubitemid 40807025)
54. Pal. S.; Ravindran, R.; Ali, N. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani imfection in Balb/c mice. Antomicrob. Agents Chemother., 2004, 48, 3591-3593. (Pubitemid 39129369)
55. Lala, S.; Pramanick, S.; Mukhopadhyay, S.; Bandyopadhyay, S.; Basu, M. Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. J. Drug Target., 2004, 12, 165-175.
56. Mukherjee, S.; Das, L.; Kole, S.; Karmakar, S.; Datta, N.; Das, P. Targeting of parasite specific immunoliposome-encapulated doxorubicin in the treatment of experimental visceral leishmaniasis. J. Infect. Dis., 2004, 189, 1024-1034. (Pubitemid 38373095)
57. Antimisiaris, S.; Klepetsanis, P.; Zachariou, V.; Giannopolu, E.; Ioannou, P. In vivo distribution of arsenic after i.p. injection of arsonoliposomes in Balb/c mice. Int. J. Pharm., 2005, 289,151-158. (Pubitemid 40093549)
58. Antimisiaris, S.; Ioannou, P.; Loiseau, P. In vitro antileishmnial and trypanocidal activities of arsonoliposomes and preliminary in vivo distribution in Balb/c mice. J. Pharm. Pharmacol., 2003, 55, 647-652. (Pubitemid 36705575)
59. Zagana, P.; Klepetsanis, P.; Ioannou, P.; Loiseau, P.M.; Antimisiaris, S.G. Trypanocidal activity of arsonoliposomes: Effect of vesicle lipid composition. Biomed. Pharmacother., 2007, 61, 499-504.
60. Schettini, D.A.; Ribeiro, R.R.; Demicheli, C.; Rocha, O.G.F.; Melo, M.N.; Michalick, M.S.M.; Frézard, F. Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size. Int. J. Pharm., 2006, 315, 140-147. (Pubitemid 44275230)
61. De Oliveira, F.B.; Schettini, D.A.; Ferreira, C.S.; Rates, B.; Rocha, O.G.F.; Frézard, F.; Demicheli, C. Kinetics of antimony(V) reduction by L-cysteine. Pharmacological implications and application to the determination of antimony in pentavalent antimonial drugs. J. Braz. Chem. Soc., 2006, 17, 1642-1650.
62. Christensen, D.; Korsholm, K.S.; Rosenkrands, I.; Lindenstrom, T.; Andersen, P.; Agger, E.M. Cationic liposomes as vaccine adjuvants. Exp. Rev. Vaccines., 2007, 6, 785-796.
63. Banerjee, A.; Roychoudhury, J.; Ali, N. Stearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine. J. Antimicrob. Chemother., 2008, 61, 103-110.
64. Mourão, S.C.; Costa, P.I.; Salgado, H.R.N.; Gremião, M.P.D. Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int. J. Pharm., 2005, 295,157-162.
65. Yardley, V.; Croft, S. In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infection. Am. J. Trop. Med. Hyg., 1999, 61, 193-197. (Pubitemid 29380248)
66. Yoshihara, E.; Tachibana, H.; Nakae, T. Trypanocidal activity of the steary-lamine-bearing liposome in vitro. Life Sci., 1987, 40, 2153-2159. (Pubitemid 17082407)
67. Morilla, M.; Montanari, J.; Prieto, M.; Lopez, M.; Petray, P.; Romero, E. Intravenous liposomal benznidazole as trypanocidal agent:increasing drug deliveryto liver is not enough. Int. J. Pharm., 2004, 278, 311-318. (Pubitemid 38759504)
68. Morilla, M.; Montanari, J.; Frank, F.; Malchiodi, E.; Corral, R.; Petray, P.; Romero, E. Etanidazole in pH-sensitive liposomes: design characterization and in vitro/in vivo anti-Trypanosoma cruzi activity. J. Control. Release, 2005, 103, 599-607. (Pubitemid 40471018)
69. Chono, S.; Tanino, T.; Seki, T.; Morimoto, K. Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J. Drug Target., 2006, 14, 557-566. (Pubitemid 44592889)
70. De Steenwinkel, J.E.M.; van Vianen, W.; Ten-Kate, M.T.; Verbrugh, H.A.; Van Agtmael, M.A.; Schiffelers, R.M.; Bakker-Woundenberg, I.A.J.M. Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice. J. Antimicrob. Chemother., 2007, 60, 1064-1073.
71. Sosunov, V.; Mischenko, V.; Eruslanov, B.; Svetoch, E.; Shakina, Y.; Stern, N.; Majorov, K.; Sorokoumova, G.; Selishcheva, A.; Apt, A. Antimycobacterial activity of bacteriocins and their complexes with liposomes. J. Antimicrob. Chemother., 2007, 59, 919-925. (Pubitemid 47073363)
72. Bhavane, R.; Karathanasis, E.; Annapragada, A.V. Triggered release of ciprofloxacin from nanostructured agglomerated vesicles. Int. J. Nanomed., 2007, 2, 407-418.
73. De Conti, R.; Gimenez, S.M.M.; Haun, M.; Pilli, R.A.; De Castro, S.L; Durán, N. Synthesis and biological activities of N,N-dimethyl-2-propen-1- amine derivatives. Eur. J. Med. Chem., 1996, 31, 915-918.
74. De Souza, A.O.; Aily, D.C.G.; Sato, D.N.; Durán, N. In-vitro activity of N,N-dimethyl-2-propen-1-amines against Mycobacterium tuberculosis. J. Antimicrob. Chemother., 1998, 42, 407-408.
75. De Souza, A.O.; Junior, R.R.S.; Ferreira-Julio, J.F.; Rodriguez, J.A.; Melo, P.S.; Haun, M.; Sato, D.N.; Duran, N. Synthesis, antimycobacterial activities and cytotoxicity on V79 of 3-[4′-Y-(1,1′-biphenyl)-4-yl]- N,N-dimethyl-3-(4-X-phenyl)-2-propen-1-amine derivatives. Eur. J. Med. Chem., 2001, 36, 843-850. (Pubitemid 34001629)
76. De Souza, A.O.; Pereira, D.G.; Durán, N. Structure and activity of aromatic propenamine derivatives. Ann. Rev. Biomed. Sci., 2002, 4, 53-78.
77. De Souza, A.O.; Hemerly, F.P.; Busollo, A.C.; Melo, P.S.; Machado, G.M.C.; Miranda, C.C.; Santa-Rita, R.M.; Haun, M.; Leon, L.L.; Sato, D.N.; De Castro, S.L.; Durán, N. 3-[4′-Bromo-(1,1′-biphenyl)-4-yl]-N, N-dimethyl-3-(2-thienyl)-2-propen-1-amine:Synthesis, cytotoxicity, and leishmanicidal, trypanocidal and antimycobacterial activities. J. Antimicrob. Chemother., 2002, 50, 629-637. (Pubitemid 35331679)
78. De Souza, A.O.; Santos, R.R.; Sato, D.N.; De Azevedo, M.M.M.; Ferreira, D.A.; Melo, P.S.; Haun, M.; Silva, C.L.; Duran, N. Free 2-propen-1-amine derivative and inclusion complexes with β-cyclodextrin: Scanning electron microscopy, dissolution, cytotoxicity and antimycobacterial activity. J. Braz. Chem. Soc., 2004, 15, 682-689. (Pubitemid 39573301)
79. De Souza, A.O.; Alderete, J.B.; Faljoni-Alario, A.; Silva, C.L.; Durán, N. Physico-Chemical characterization of the inclusion complex between a 2-propen-1-amine derivative and β-cyclodextrin. J. Chil. Chem. Soc., 2005, 50, 591-596.
80. De Souza, A.O.; Santana, M.H.A.; Silva, C.L.; Durán, N. Cytotoxicity and antimycobacterial activity of free and liposome-encapsulated 3-(4′-bromo[1,1′-biphenyl-4-yl)-3-(4-bromo-phenyl)-N, N-dimethyl-2-propen-1-amine (BBAP). Open J. Pharm. Sci. Submitted 2009.
81. El-Ridy, M.S.; Mostafa, D.M.; Shehab, A.; Nasr, E.A.; El-Alim, A.S. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int. J. Pharm., 2007, 330, 82-88.
82. Troshkina, A.O.; Salinas, E.G.; Sorokoumova, G.M.; Kaprelyants, A.S.; Selishcheva, A.A. The effect of liposomes on the growth and sensitivity of Mycobacterium smegmatis to isoniazide. Appl. Biochem. Microbiol., 2007, 43, 41-46.
83. Rosada, R.S.; de la Torre, L.G.; Frantz, F.G.; Trombone, Ana P. F.; Zarate-Blades C.R.; Fonseca D.M.; Souza P.R.M.; Brandao I.T.; Masson A.P.; Soares E.G.; Ramos S.G.; Faccioli L.H.; Silva C.L.; Santana M.H.A.; Coelho-Castelo A.A.M. Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes. BMC Immunol., 2008, 9, 38.
84. Bisht, V.; Chattree, V.; Khanna, N.; Rao, D.N. Mycobacterial formulation in liposomes showed decreased expression of CD95/CD95L and caspase activity in T cells of leprosy patients. Curr. Appl. Phys., 2005, 5, 189-193.
85. Patel, V.B.; Misra, A.N. Encapsulation and stability of clofazimine liposomes. J. Microencapsul., 1999, 16, 357-367.
86. Patel, V.B.; Misra, A.N.; Marfatia, Y.S. A topical dosage form of liposomal clofazimine: research and clinical implications. Pharmazie, 1999, 54, 448-451.
87. Owais, M.; Misra-Bhattacharya, S.; Haq, W.; Gupta, C.M. Immunomodulator tuftsin augments antifilarial activity of diethylcarbamazine against experimental brugian filariasis. J. Drug Target., 2003, 11, 247-251.
88. Bajpai, P.; Vedi, S.; Owais, M.; Sharma, S.K.; Saxena, P.N.; Misra-Bhattacharva, S. Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model. J. Drug Target., 2005, 13, 375-381.
89. Leslie, T.A.; Goldsmith, P.C.; Dowd, P.M. Fungal and parasitic skin infestations - an update in treatment. Curr. Opin. Infect. Dis., 1993, 6, 658-667.
90. Mosqueira, V.C.F.; Loiseau, P.M.; Bories, C.; Legrand, P.; Devissaguet, J.P.; Barrat, G. Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice. Antimicrob. Agents Chemother., 2004, 48, 1222-1228.
91. Mosqueira, V.C.F.; Legrand, P.; Barrat, G. Surface-modified and conventional nanocapsules as novel formulations for parental delivery of halofantrine. J. Nanosci. Nanotechnol., 2006, 6, 3193-3202.
92. Leite, E.A.; Grabe-Guimarães, A.; Guimarães, H.M.; Machado-Coelho, G.L.L.; Barrat, G.; Mosqueira, V.C.F. Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices. Life Sci., 2007, 80, 1327-1334. (Pubitemid 46320453)
93. Foger, F.; Noopakdee, W.; Loretz, B.; Joojuntr, S.; Salvenmoser, W.; Thaler, M.; Bernkop-Schnurch, A. Inhibition of malarial topoisomerase II in Plasmodium falciparum by antisense nanoparticles. Int. J. Pharm., 2006, 319, 139-146. (Pubitemid 44051799)
94. Joshi, M.D.; Patravale, V. Nanostructured lipid carrier (NLC) of beta-artemether: potential in the treatment of cerebral malaria. Proc. 1st. Indo-Japanese Intern. Conf. Adv. Pharm. Res. Technol., 2005, 1, 110.
95. Bhadra, D.; Bhadra, S.; Jain, N.K. PEGylated peptide-based dendritic nanoparticulate systems for delivery of artemether. J. Drug Deliv. Sci. Technol., 2005, 15, 65-73. (Pubitemid 40208981)
96. Costa, F.T.M.; Lopes, S.C.P.; Nogueira. P.A.; Justo, G.Z.; Durán, N. Use of violacein in a free or encapsulated in polymeric systems against malaria. Brazilian Patent PIBr; 0506399-506400, 2006.
97. Mbela, T.K.M.; Oupaert, J.H.; Dumont, P. Poly(diethylmethylidene malonate) nanoparticles as promaquine delivery system to liver. Int. J. Pharm., 1992, 79, 29-38.
98. Labhasetwar, V.D.; Dorle, A.K. Nanoparticle-A colloidal drug delivery system for primaquine and metronidazole. J. Control. Release, 1990, 12, 113-119.
99. Singh, K.K.; Vingkar, S.K. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int. J. Pharm., 2008, 347, 136-143.
100. Bajpai, A.K.; Choubey, J. Design of gelatin nanoparticles as swelling controlled delivery system for chloroquine phosphate. J. Mater. Sci. Mater. Med., 2006, 17, 345-358.
101. Gupta, Y.; Jain, A.; Jain, S.Y. Transferring-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol., 2007, 59, 935-940.
102. Costa, F.T.; Avril, M.; Nogueira, P.A.; Gysin, J. Cytoadhesion of Plasmodium falciparum-infected erythrocytes and the infected placenta: a two-way pathway. Braz. J. Med. Biol. Res., 2006, 39, 1525-1536 (Pubitemid 46357838)
103. Lopes, S.C.P.; Blanco, Y.C.; Nogueira, P.A.; Rodrigues, F.L.S.; Justo, G.Z.; Duran, N.; Costa, F.T.M. Evaluation of the in vivo and in vitro antiplasmodium activity of the violacein extracted from Chromobacterium violaceum. XXII Annual Meeting of the Brazilian Society of Protozoology, 2006, Caxambu. Abstr. QT25, 2006, 195.
104. Leon, L.L.; Miranda, C.C.; De Souza, A.O.; Durán, N. Antileishmanial activity of the violacein extracted from Chromobacterium violaceum. J. Antimicrob. Chemother., 2001, 48, 449-450. (Pubitemid 32898824)
105. Durán, N.; De Azevedo, M.M.M. Polymeric nanoparticles encapsulating a pharmaceutical or cosmetics compounds, their process and cosmetic or pharmaceutical formulation. Brazilian Patent PIBr; 0100199-100200, 2004.
106. Durán, N.; Justo, G.Z.; Ferreira, C.V.; Melo, P.S.; Cordi, L.; Martins, D. Violacein: Properties and biological activities. Biochem. Appl. Biotechnol., 2007, 48, 127-133.
107. Lala, S.; Gupta, S.; Sahu, N.P.; Mandal, D.; Mandal, N.B.; Moulik, S.P.; Basu, M.K. Critical evaluation of the therapeutic potential of bassic acid incorporated in oil-in-water microemulsions and poly-D,L-lactide nanoparticle against experimental. J. Drug Target., 2006, 14, 171-179.
108. Tyagi, R.; Lala, S.; Verma, A.; Nandy, A.; Mahato, S.; Marita, A.; Basu, M. Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. J. Drug Target., 2005, 13, 161-171. (Pubitemid 40668169)
109. Gaspar, R.; Preat, V.; Roland, M. Nanoparticles of polyisohexylcyanoacrylate (PIHCA) as carriers of primaquine - formulation, physicochemical characterization and acute toxicity. Int. J. Pharm., 1991, 68, 111-119.
110. Gaspar, R.; Opperdoes, F.; Preat, V.; Ronald, M. Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. Ann. Trop. Med. Parasitol., 1992, 86, 41-49.
111. Heurtault, B.; Legrand, P.; Mosqueira, C.C.F.; Devissaguet, J.P.; Barrat, G.; Bories, C. The antileishmanial properties of surface modified and primaquine- loaded nanocapsules tested against intramacrophagic Leismania donovani amastigotes in vitro. Ann. Trop. Med. Parasitol., 2001, 95, 529-533. (Pubitemid 32730487)
112. Paul, M.; Durand, R.; Boulard, Y.; Fusai, T.; Fernandez, C.; Rivollet, D.; Deniau, M.; Astier, A. Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmaia major infected mice. J. Drug Target., 1998, 5, 481-490. (Pubitemid 28499682)
113. Amarji, B.; Ajazuddin, R.; Rqghuwanshi, D.; Vyas, S.P.; Kanaujia, P. Lipid nano spheres (LNSs) for enhanced oral bioavailability of amphotericin B: Development and characterization. J. Biomed. Nanotechnol., 2007, 3, 264-269. (Pubitemid 351877152)
114. Feng, Z.Q.; Zhong, S.G.; Li, Y.H.; Li, Y.Q.; Qiu, Z.N.; Wang, Z.M.; Li, J.; Dong, L.; Guan, X.H. Nanoparticles as a vaccine adjuvant of anti-idiotypic antibody against schistosomiasis. Chin. Med. J., 2004, 117, 83-87.
115. Mainardes, R.M.; Chaud, M.V.; Gremião, M.P.D.; Evangelista, R.C. Development of praziquantel-loadd PLGA nanoparticles and evaluation of intestinal permeation by the everted gut Sac model. J. Nanosci. Nanotechnol., 2006, 6, 3057-3061. (Pubitemid 44579982)
116. Araujo, S.C.; Mattos, A.C.A.; Teixeira, H.F.; Coelho, P.M.Z.; Nelson, D.L.; Oliveira, M.C. Improvement of in vitro efficacy of a novel schistosomicidal drug by incorporation into nanoemulsions. Int. J. Pharm., 2007, 337, 307-315. (Pubitemid 46778956)
117. Durán, N.; Menck, C.F.M.. Chromobacterium violaceum: A Review on pharmacological and industrial perspectives. Crit. Rev. Microbiol., 2001, 27, 201-222. (Pubitemid 32929896)
118. Durán, N.; Campos, V.; Riveros, R.; Joyas, A.; Pereira, M.F.; Haun, M. Bacterial Chemistry-III: Preliminary studies on trypanosomal activities of Chromobacterium violaceum products. An. Acad. Bras. Ciênc., 1989, 61, 31-36.
119. Durán, N.; Haun, M. Trypanocide. State of Art. Mem. Inst. Oswaldo Cruz, 1991, 86 (Suppl. I), 29-30.
120. Sanchez, G.; Cuellar, D.; Zulantay, I.; Gajardo, M.; Gonzalez-Martin, G. Cytotoxicity and trypanocidal activity of nifurtimox encapsulated in ethyl-cyanoacrylate nanoparticles. Biol. Res., 2002, 35, 39-45.
121. González -Martín, G.; Figueroa, C.; Merino, I.; Osuna, A. Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosoma-tropic carrier: preparation and trypanocidal activity. Eur. J. Pharm. Biopharm., 2000, 49, 137-142. (Pubitemid 30126061)
122. Urbina, J.A. Specific treatment of Chagas' disease: current status and new developments. Curr. Opin. Infect. Dis., 2001, 14, 733-741. (Pubitemid 33141196)
123. Molina, J.; Urbina, J.A.; Gref, R.; Brener, Z.; Rodriguez, J.M. Cure of experimental Chagas' disease by the bis-triazole D0870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres. J. Antimicrob. Chemother., 2001, 47, 101-104.
124. Olbrich, C.; Gessner, A.; Kayser, O.; Muller, R. Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J. Drug Target., 2002, 10, 387-396. (Pubitemid 34906164)
125. Flaig, R.; Rosenkranz, V; Wink, M.; Fricker, G. Ktenate nanoparticles (bdellosomes): a novel strategy for delivering drugs to parasites or tumors. J. Drug Deliv. Sci. Technol., 2005, 15, 59-63. (Pubitemid 40208980)
126. Schwinté, P.; Ramphul, M.; Darcy, R.; O'Sullivan, J.F. Amphiphilic cyclodextrin complexation of clofazimine. J. Incl. Phenom. Macro. Chem., 2003, 47, 109-112.
127. De Souza, A.O.; Aily, D.C.G.; Sato, D.N.; Durán, N. In vitro activity of violacein against Mycobacterium tuberculosis H37Ra. Rev. Inst. Adolfo Lutz, 1999, 58, 59-62.
128. Sharma, A.; Pandey, R.; Skarma, S.; Khuller, G.K. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int. J. Antimicrob. Agents, 2004, 24, 599-604.
129. Zahoor, A.; Sharma, S.; Khuller, G.K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents, 2005, 26, 298-303. (Pubitemid 41338657)
130. Pandey, R.; Sharma, S.; Khuller, G.K. Oral solid lipid nanoparticles-based antitubecular chemotherapy. Tuberculosis, 2005, 85, 415-420. (Pubitemid 41617396)
131. Pandey, R.; Khuller, G.K. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J. Antimicrob. Chemother. 2006, 57, 1146-1152.
132. Kumar, P.V.; Asthana, A.; Dutta, T.; Jain, N.K. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J. Drug Target., 2006, 14, 546-556.
133. Durán, N.; Alvarenga, M.A.; Marcato, P.D.; Melo, P.S. Microencapsulation of antibiotic rifampicin in poly(3-hydroxybutyrate-co-3- hydroxyvalerate). J. Pharm. Pharmacol. 2008, 31, 1509-1516.
134. Durán, N.; De Oliveira, A.F.; De Azevedo, M.M.M. In vitro studies on the release of isoniazid incorporated in poly(ε-caprolactone). J. Chemother., 2006, 18, 473-479. (Pubitemid 44776157)
135. Ahmad, Z.; Pandey, R.; Sharma, S.; Khuller, G.K. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int. J. Antimicrob. Agents., 2006, 27, 409-416.
136. Ahmad, Z.; Sharma, S.; Khuller, G.K. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomed. Nanotechnol. Biol. Med., 2007, 3, 239-243.
137. Bivas-Benita, M.; van Meijgaarden, K.E.; Franken, K.L.; Junginger, H.E.; Borchard, G.; Ottenhoff, T.H.; Geluk, A. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A-0201 -restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine, 2004, 22, 1609-1615. (Pubitemid 38447207)
138. Kisich, K.O.; Gelperina, S.; Higgins, M.P.; Wilson, S.; Shipulo, E.; Oganesyan, E.; Heifets, L. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. Int. J. Pharm., 2007, 345, 154-162. (Pubitemid 350087550)
139. Karajgi, J.S.; Vuas, S.P. A lymphotropic colloidal carrier system for diethylcarbamazine: preparation and performance evaluation. J. Microencapsul., 1994, 11, 539-545.
140. Green, S.; Fortier, A.; Dijkstra, J.; Madsen, J.; Swartz, G.; Einck, L.; Gubish, E.; Nancy, C. Liposomal vaccines. Adv. Exp. Med. Biol., 1995, 383, 83-92.
141. Hien, T.; Davis, T.; Chuong, L.; Ilett, K.; Sinh, D.; Phu, N.; Agus, C.; Chiswell, G.; White, N.; Farrar, J. Comparative pharmacokinetics of instramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob. Agents Chemother., 2004, 48, 4234-4239. (Pubitemid 39434880)
142. Agatha, W.; Wasan, K. Development of liposomal polyene antibiotics: a historical perspectives. J. Pharm. Pharmacol. Sci., 2003, 6, 67-83. (Pubitemid 37207242)
143. Chambers, M.A.; Wright, D.C.; Brisker, J.; Williams, A.; Hatch, G.; Gavier-Widen, D.; Hall, G.; Marsh, P.D.; Glyn-Hewinson, R. A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome) protects guinea pigs from lethal tuberculosis. Vaccine, 2004, 22, 1063-1071.